Lv2
118 积分 2024-06-20 加入
Impact of age and comorbidity on treatment of non-small cell lung cancer recurrence following complete resection: A nationally representative cohort study
1个月前
已完结
[18F]FDG PET-CT radiomics signature to predict pathological complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: a multicenter study
2个月前
已完结
MA04.10 Comprehensive Peripheral Blood Immunophenotyping and T-Cell Clonal Analysis During Neoadjuvant Immunotherapy with Atezolizumab in NSCLC
2个月前
已完结
Circulating PD-L1+ exosomes as potential prognostic and predictive biomarkers in pulmonary lymphoepithelioma-like carcinoma
2个月前
已关闭
P1.03D.04 Circulating APOBEC Signature as a Non-Invasive Biomarker Delineating Potential Responder to Neoadjuvant Immunotherapy for IIIA-N2 NSCLC
2个月前
已关闭
OA01.03 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC
2个月前
已关闭
Artificial Intelligence–Powered Assessment of Pathologic Response to Neoadjuvant Atezolizumab in Patients With NSCLC: Results From the LCMC3 Study
2个月前
已完结
Artificial intelligence (AI)–powered pathologic response (PathR) assessment of resection specimens after neoadjuvant atezolizumab in patients with non-small cell lung cancer: Results from the LCMC3 study
2个月前
已完结
EP.07H.01 Analysis of Variables Predicting pCR and irAEs in Resectable NSCLC Receiving Neoadjuvant Immunotherapy with Chemotherapy (Pre-PLaN)
2个月前
已完结
EP.07H.01 Analysis of Variables Predicting pCR and irAEs in Resectable NSCLC Receiving Neoadjuvant Immunotherapy with Chemotherapy (Pre-PLaN)
2个月前
已完结
皖公网安备34019202002308
